Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.73 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10651388 | 0.98 | CHRM3 (0.76) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL10651354 | 0.86 | CHRM3 (0.97) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL10436572 | 0.86 | HTR2C (0.96) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL10656906 | 0.84 | CHRM3 (1.00) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL10460428 | 0.79 | CHRM3 (1.00) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL10460426 | 0.78 | CHRM3 (0.97) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL12292410 | 0.76 | CHRM3 (0.46) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL5533785 | 0.76 | CHRM3 (0.46) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL247815 | 0.76 | CHRM3 (0.46) | HTR2CCHRM3CHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL1403323 | 0.74 | CHRM3 (0.45) | HTR2CCHRM3CHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | Certego Therapeutics Inc. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | HTR2C 52/4885CHRM3 1651/4885CHRM5 1501/4885 |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | GABRD, GABRA6, GABRA3 | HTR2C 52/4885CHRM3 1651/4885CHRM5 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.